Naperville, IL -- (SBWIRE) -- 03/20/2015 -- Reportstack, provider of premium market research reports announces the addition of Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023 market report to its offering

Tenapanor (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients quality of life (QOL). In terms of volume, the IBS market is a large, albeit nave, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Tenapanor is being developed for the treatment of IBS-C. It was initially developed by Ardelyx, but in October 2012, the company entered into a partnership with AstraZeneca, which gained the exclusive worldwide licensing rights to tenapanor (Ardelyx, press release, October 8, 2012).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Tenapanor including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Tenapanor for the top 7 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.

- Stay ahead of the competition by understanding the changing competitive landscape for IBS.

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

- Make more informed business decisions from insightful and in-depth analysis of Tenapanor performance.

- Obtain sales forecast for Tenapanor from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Complete report is available
http://www.reportstack.com/product/194762/tenapanor-irritable-bowel-syndrome-forecast-and-market-analysis-to-2023.html

Contact:
Roger Campbell
roger@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604